Argireline vs Rigin

Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects

Argireline (Acetyl Hexapeptide-3) is a synthetic hexapeptide applied topically in cosmetic formulations to reduce the appearance of expression lines. It is proposed to partially inhibit the SNAP-25 component of the SNARE protein complex, attenuating the strength of muscle contractions that drive dynamic wrinkle formation. Controlled human trials have demonstrated statistically significant reductions in wrinkle depth with repeated topical application compared to placebo, representing some of the stronger human evidence available for a cosmetic peptide. Argireline is classified as a cosmetic ingredient, not a drug; it has not been evaluated by the FDA for efficacy and existing evidence is limited to cosmetic endpoints in small-to-medium trials. Argireline concentration and use: in published cosmetic studies, argireline is used at concentrations of 5–10% in topical formulations, applied to areas of dynamic expression lines such as forehead and periorbital regions. The mechanism of action — partial SNARE complex inhibition rather than complete neurotoxin-class blockade — means the effect is typically described as softening expression line depth rather than eliminating muscle movement. Results in human studies develop over 4–8 weeks of twice-daily application. Argireline vs SNAP-8: SNAP-8 (Acetyl Octapeptide-3) is a longer structural derivative of argireline developed to extend SNARE complex competitive inhibition further along the docking sequence, with manufacturer-sponsored data suggesting improved potency at lower concentrations. The key difference in evidence quality: argireline has independent peer-reviewed human trial data, while SNAP-8 data originates primarily from manufacturer-sponsored studies not indexed in standard biomedical literature. Both are topical cosmetic ingredients and neither carries regulatory drug approval. For cosmetic peptides with more systemic research profiles — including GHK-Cu, which has several decades of independent research — the PeptideBase skin and joint peptides directory covers the broader landscape.

Palmitoylated tetrapeptide mimicking IgG C-terminal sequence; reduces IL-6 production in keratinocytes; combined with Matrixyl (Pal-GHK) forms Matrixyl 3000; anti-inflammatory and skin matrix support

Rigin (Palmitoyl Tetrapeptide-7) is a synthetic cosmetic peptide developed to address skin inflammation and age-related matrix degradation. It is proposed to suppress interleukin-6 (IL-6), a cytokine associated with chronic low-grade skin inflammation that accelerates extracellular matrix breakdown. Evidence for rigin is primarily derived from manufacturer-sponsored in vitro and ex vivo cosmetic research; no independent peer-reviewed clinical trials have been identified in indexed biomedical literature. Rigin is a cosmetic ingredient developed by Sederma/Croda; its evidence base consists of manufacturer-sponsored studies only and it has not been evaluated by regulatory agencies for any medicinal claim. Rigin and Matrixyl 3000 Rigin (Palmitoyl Tetrapeptide-7, Pal-GQPR) is one of two peptide actives in Sederma's Matrixyl 3000 formulation — the other being Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS). In the Matrixyl 3000 combination, the two peptides are proposed to address complementary aspects of skin aging: Matrixyl (Pal-KTTKS) stimulates new collagen I and III synthesis via TGF-β signaling; Rigin (Pal-GQPR) suppresses IL-6-mediated matrix degradation, reducing the rate at which newly synthesised collagen is broken down. The combination therefore targets both the anabolic (synthesis) and anti-catabolic (degradation prevention) sides of collagen matrix maintenance. This mechanistic pairing is the basis for the "3000" formulation's improved efficacy claims relative to the original single-peptide Matrixyl. In cosmetic formulations, Rigin is listed under its INCI name (Palmitoyl Tetrapeptide-7) and appears alongside palmitoyl pentapeptide-4 in products marketed as containing Matrixyl 3000. Typical concentration in the final product is in the range of 4–8% of the Sederma Matrixyl 3000 concentrate, which itself contains the peptides at a defined dilution. Rigin is a topical cosmetic ingredient — it has no injectable or clinical pharmaceutical application and does not require a prescription in any jurisdiction.